Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 7/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407745 | 0.85 | PRKAB2 (0.47) | MAP2K4MAPK1MAPK6MAPKAPK3ALDH1A1 | |
| SCHEMBL4399990 | 0.81 | JAK2 (0.41) | MAP2K4MAPK1MAPK6MAPKAPK3JAK2 | |
| SCHEMBL23675227 | 0.81 | MAP2K4 (0.54) | MAP2K4KDM4EALDH1A1HPGDJAK2 | |
| SCHEMBL29564826 | 0.81 | MAP2K4 (0.54) | MAP2K4KDM4EALDH1A1HPGDJAK2 | |
| SCHEMBL2671070 | 0.81 | MAP2K4 (0.55) | MAP2K4MAPK1MAPK6MAPKAPK3KDM4E | |
| SCHEMBL117222 | 0.81 | JAK2 (0.64) | MAP2K4MAPK1MAPK6MAPKAPK3KDM4E | |
| SCHEMBL2463004 | 0.80 | MAP2K4 (0.44) | MAP2K4MAPK1MAPK6KDM4EALDH1A1 | |
| SCHEMBL2462240 | 0.80 | PARP1 (0.45) | MAP2K4MAPK1MAPK6KDM4ETSHR | |
| SCHEMBL1145076 | 0.79 | MAP2K4 (0.57) | MAP2K4MAPK1MAPK6MAPKAPK3KDM4E | |
| SCHEMBL2560742 | 0.79 | MAP2K4 (0.50) | MAP2K4MAPK1MAPK6MAPKAPK3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2297163-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144554-A1 | PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS | PFIZER, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | SGK2, SGK1, SGK3 | MAP2K4 1011/4885MAPK1 686/4885MAPK6 1594/4885 |
| US-20110028390-A1 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | MAP2K4 2469/4885MAPK1 1613/4885MAPK6 2162/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | MAP2K4 4241/4885MAPK1 2252/4885MAPK6 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.